Free shipping on all orders over $ 500

Enavatuzumab

Cat. No. M24544
Enavatuzumab Structure
Synonym:

PDL192; ABT-361

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

Chemical Information
CAS Number 1062149-33-0
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Shiming Ye, et al. J Immunol Res. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

[2] Elaine T Lam, et al. Mol Cancer Ther. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

[3] Ludmilla de Plater, et al. PLoS One. Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts

[4] James W Purcell, et al. Front Immunol. Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

[5] Debra T Chao, et al. J Cancer Res Clin Oncol. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

Related TNF Receptor Products
Chilob7/4

Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies.
VIB4920

VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates.
ABBV-428

ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors.
TNF-α (31-45), human

TNF-α (31-45), human is a potent NF-kB pathway activator.
LEESGGGLVQPGGSMK

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab.
  Catalog
Abmole Inhibitor Catalog




Keywords: Enavatuzumab, PDL192; ABT-361 supplier, TNF Receptor, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.